| US 7,405,043 B2 | ||
| Responsiveness to therapy for liver disorders | ||
| Yuchi Hwang, Taipei (Taiwan); Kuang-Den Chen, Taipei (Taiwan); Chingwei Chang, Taipei (Taiwan); Jui-Lin Chen, Taoyuan (Taiwan); Ding-Shinn Chen, Taipei (Taiwan); Pei-Jer Chen, Taipei (Taiwan); and Ming-Yang Lai, Taipei (Taiwan) | ||
| Assigned to Vita Genomics, Inc., Taipei (Taiwan) | ||
| Filed on Jun. 29, 2004, as Appl. No. 10/880,315. | ||
| Prior Publication US 2005/0288497 A1, Dec. 29, 2005 | ||
| Int. Cl. C12Q 1/68 (2006.01) | ||
| U.S. Cl. 435—6 | 4 Claims |
| 1. A method of evaluating responsiveness of a subject to a drug, comprising
providing a nucleic acid sample from a subject;
determining a single nucleotide polymorphism genotype of a gene group that includes the human ADAR, CASP5, FGF1, ICSBP1, IFI44,
PIK3CG, TAP2, and TGFBRAP1 genes; and
comparing the single nucleotide polymorphism genotype of the human ADAR, CASP5, FGF1, ICSBP1, IFI44, PIK3CG, TAP2, and TGFBRAP1
genes with a predetermined single nucleotide polymorphism genotype for each of human ADAR, CASP5, FGF1, ICSBP1, IFI44, PIK1CG,
TAP2, and TGFBRAP1 genes,
whereby the subject is predicted to be responsive or non-responsive to the drug if the single nucleotide polymorphism genotype
is identical to a predetermined single nucleotide polymorphism genotype of the human ADAR, CASP5, FGF1, ICSBP1, IFI44, PIK3CG,
TAP2, and TGFBRAP1 genes.
|